Rashtriya Newsflash

“Spasticity Pipeline Insight, 2026“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Spasticity Market.

The Spasticity Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Spasticity Pipeline Report:

• Companies across the globe are diligently working toward developing novel Spasticity treatment therapies with a considerable amount of success over the years.

• Spasticity companies working in the treatment market are Lundbeck, Revance Therapeutics, Ipsen, Saol Therapeutics, Huons, Supernus Pharma, Sun Pharma, Acorda Therapeutics, Merz Pharmaceuticals GmbH, Medy-Tox, XenoPort, Inc., Medtronic Neuro, Daewoong Pharma, and others, are developing therapies for the Spasticity treatment

• Emerging Spasticity therapies in the different phases of clinical trials are- Lu AG06466, DAXXIFY, IPN10200, SIL 1002, HU-014, MYOBLOC, SPARC1103, Tizanidine, CORETOX®, XP19986 SR1, intrathecal baclofen, Botulinum toxin type A, and others are expected to have a significant impact on the Spasticity market in the coming years.

• In June 2026, Pipeline development continued to focus on enhancing treatment durability, precision drug delivery systems, neuromodulation technologies, and personalized rehabilitation approaches to improve long-term functional outcomes for individuals living with chronic spasticity.

• In January 2026, Multiple Phase II and Phase III clinical trials continued to assess innovative intrathecal baclofen delivery systems, next-generation botulinum toxin formulations, and neuromodulation technologies for the treatment of spasticity associated with stroke, multiple sclerosis, spinal cord injury, and cerebral palsy.

• In July 2025, A global Phase II clinical trial, BALANCE-MSS-1 (NCT06782490), has been launched to evaluate BMS-986368, an investigational oral therapy, for the treatment of spasticity associated with multiple sclerosis (MS), characterized by muscle stiffness and spasms. The study plans to enroll approximately 200 adults with MS who have experienced spasticity for at least six months. Recruitment is underway at sites across the United States, Australia, Canada, Puerto Rico, and several European countries. The trial is sponsored by Celgene and is being conducted by Bristol Myers Squibb, which acquired Celgene in 2019.

• In April 2025, The US FDA has approved BlackfinBio’s IND application to initiate a Phase I/II trial of BFB-101, an adeno-associated virus gene therapy for hereditary spastic paraplegia type 47 (SPG47). The therapy has also received orphan drug and rare pediatric disease designations for SPG47, a rare disorder caused by AP4B1 gene mutations, leading to progressive lower-limb spasticity and developmental delays in children.

• In March 2025, BlackfinBio Limited announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its innovative adeno-associated virus (AAV) gene therapy designed to treat Hereditary Spastic Paraplegia Type 47 (SPG47).

Spasticity Overview

Spasticity is a condition characterized by an abnormal increase in muscle tone or stiffness, which can interfere with movement, speech, and gait. It is caused by damage to or a disruption in the pathways that control muscle movement, typically within the brain or spinal cord.

Get a Free Sample PDF Report to know more about Spasticity Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/spasticity-pipeline-insight

Emerging Spasticity Drugs Under Different Phases of Clinical Development Include:

• Lu AG06466: Lundbeck

• DAXXIFY: Revance Therapeutics

• IPN10200: Ipsen

• HU-014: Huons

• SL-1002: Saol Therapeutics Inc

• MYOBLOC: Supernus Pharma

• SPARC1103: Sun Pharma

• Tizanidine: Acorda Therapeutics

• botulinum A toxin: Merz Pharmaceuticals GmbH

• CORETOX®: Medy-Tox

• XP19986 SR1: XenoPort, Inc.

• intrathecal baclofen: MedtronicNeuro

Spasticity Route of Administration

Spasticity pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Spasticity Molecule Type

Spasticity Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

Spasticity Pipeline Therapeutics Assessment

• Spasticity Assessment by Product Type

• Spasticity By Stage and Product Type

• Spasticity Assessment by Route of Administration

• Spasticity By Stage and Route of Administration

• Spasticity Assessment by Molecule Type

• Spasticity by Stage and Molecule Type

DelveInsight’s Spasticity Report covers around 12+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Spasticity product details are provided in the report. Download the Spasticity pipeline report to learn more about the emerging Spasticity therapies

Spasticity Pipeline Analysis:

The Spasticity pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Spasticity with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Spasticity Treatment.

• Spasticity key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Spasticity Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Spasticity market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Spasticity drugs and therapies

Spasticity Pipeline Market Drivers

• Increasing prevalence of stroke, multiple sclerosis, and brain injury drive the market, increasing R&D for developing effective therapies are some of the important factors that are fueling the Spasticity Market.

Spasticity Pipeline Market Barriers

• However, high cost of the treatment, lack of disease awareness in emerging economies and other factors are creating obstacles in the Spasticity Market growth.

Scope of Spasticity Pipeline Drug Insight

• Coverage: Global

• Key Spasticity Companies: Lundbeck, Revance Therapeutics, Ipsen, Saol Therapeutics, Huons, Supernus Pharma, Sun Pharma, Acorda Therapeutics, Merz Pharmaceuticals GmbH, Medy-Tox, XenoPort, Inc., Medtronic Neuro, Daewoong Pharma, and others

• Key Spasticity Therapies: Lu AG06466, DAXXIFY, IPN10200, SIL 1002, HU-014, MYOBLOC, SPARC1103, Tizanidine, CORETOX®, XP19986 SR1, intrathecal baclofen, Botulinum toxin type A, and others

• Spasticity Therapeutic Assessment: Spasticity current marketed and Spasticity emerging therapies

• Spasticity Market Dynamics: Spasticity market drivers and Spasticity market barriers

Request for Sample PDF Report for Spasticity Pipeline Assessment and clinical trials

Table of Contents

1. Spasticity Report Introduction

2. Spasticity Executive Summary

3. Spasticity Overview

4. Spasticity- Analytical Perspective In-depth Commercial Assessment

5. Spasticity Pipeline Therapeutics

6. Spasticity Late Stage Products (Phase II/III)

7. Spasticity Mid Stage Products (Phase II)

8. Spasticity Early Stage Products (Phase I)

9. Spasticity Preclinical Stage Products

10. Spasticity Therapeutics Assessment

11. Spasticity Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Spasticity Key Companies

14. Spasticity Key Products

15. Spasticity Unmet Needs

16 . Spasticity Market Drivers and Barriers

17. Spasticity Future Perspectives and Conclusion

18. Spasticity Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/